Monoclonal antibodies are of paramount importance in diagnosis and treatment of human disease. Therefore, great technological progress has been made in the manufacturing of antibodies using mammalian expression hosts, substantially increasing yield and decreasing time to market. In parallel, much progress has been reported using the microbial production platform (E. coli) in particular for small antibody fragments like single chain, or Fab-based antibody products. Together with our collaborators, i.e. the research group of prof. dr. Gilles van Wezel (Leiden University) and prof. dr. Dan Barouch (BIDMC), we report on a novel microbial expression system for the production of recombinant proteins and antibody fragments.
Full article published in Applied Microbiology and Biotechnology: link